In a randomized trial, both 100-mg and 300-mg monthly maintenance doses of extended-release buprenorphine improved opioid abstinence in patients with high-risk opioid use, with no new safety signals.

Lev Facher covers the U.S. addiction and overdose crisis. Patients who received higher doses of buprenorphine, a common medication used to alleviate opioid withdrawal and cravings, were less likely to ...

Adults with opioid use disorder who receive a higher daily dose of the opioid addiction treatment medication buprenorphine may have a lower risk of subsequent emergency department visits or use of ...

Please provide your email address to receive an email when new articles are posted on . Only 34% of attempts were successful in low-dose initiation of buprenorphine. No significant differences in ...

Adults with opioid use disorder who receive a higher daily dose of the opioid addiction treatment medication buprenorphine may have a lower risk of subsequent emergency department visits or use of ...

For adults with high-risk opioid use disorder (OUD), both 100-mg or 300-mg monthly maintenance injections of extended-release buprenorphine improved opioid abstinence, but the higher dose seemed to ...

SAN DIEGO, California ― For infants of mothers who were treated for opioid use disorder with buprenorphine, rates of neonatal abstinence syndrome (NAS) were found to be lower compared to infants whose ...

The injectable buprenorphine will provide a much more stable basis for patients to begin their recovery from addiction to fentanyl and meth, for example, than pills taken multiple times a day, said ...

State laws that ban insurance prior authorization for buprenorphine-a leading medication for opioid use disorder-may not help more patients stay in treatment for the recommended minimum of 180 days, ...

Two dose levels of maintenance treatment with extended-release buprenorphine (Sublocade) improved opioid abstinence in patients with high-risk opioid use disorder (OUD), a randomized trial showed.